Maxence Mancini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maxence Mancini has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Maxime Battistella
INSERM U1342 Saint-Louis Research Institute , Paris
4 shared publications - Samia Mourah
Université Paris Cité, INSERM, CNRS, Institut de Recherche Saint Louis (IRSL), Paris, France
2 shared publications A. Alirkilicarslan
Department of Pathology, Grand Hôpital de l'Est Francilien-site Marne-la-Vallée, Jossigny, France
1 shared publicationAdèle De Masson
Université Paris Cité, INSERM UMR-S 976, Team 1, Human Immunology Pathophysiology and Immunotherapy (HIPI) , Paris
1 shared publication- Andreas von Deimling
Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany
1 shared publication - Anne Tallet
Platform of Somatic Tumor Molecular Genetics Université de Tours, Centre Hospitalier Universitaire de Tours Tours France
1 shared publication
Latest Publications
- 28 August 2025
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 152 (4) , 103420
Vulvar adenocarcinoma of mammary-like anogenital glands with metastatic lymph node involvement: A case report
- 28 August 2025
- Published by Elsevier in Annales de Dermatologie et de Vénéréologie
- Vol. 152 (4) , 103420
Vulvar adenocarcinoma of mammary-like anogenital glands with metastatic lymph node involvement: A case report
- 18 April 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (4) , e70049
NR1D1::MAML3 Fusion in an Aggressive Mesenchymal Neoplasm
NR1D1‐rearranged tumors are distinct mesenchymal neoplasms with epithelioid morphology and aggressive potential. This report presents an 85‐year‐old male with a slow‐growing sternal mass identified as a pseudo‐cyst, characterized by a dense proliferation of epithelioid tumor cells. These cells exhibited pale cytoplasm and uniform oval nuclei, with some areas of spindle cells and extensive necrosis. The mitotic count was 12 per 1.7 mm2. Immunohistochemical analysis showed positivity for EMA, ERG, AE1AE3, and CK7, but negativity for SMA, desmin, CD117, CD31, SOX10, MelanA, synaptophysin, INSM1, CK20, CD34, TTF1, WT1, caldesmon, myogenin, and collagen IV. INI1 expression was preserved. The Ki67 index was high. Whole‐transcriptome sequencing revealed an in‐frame NR1D1::MAML3 fusion, retaining two key protein domains of NR1D1. Nine months post‐diagnosis, the patient developed pleural, bilateral lung, and bone metastases. This case underscores the necessity of molecular analysis for precise tumor classification, given the tumor's varied morphological features and poor prognosis.
- 18 April 2025
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 64 (4) , e70049
NR1D1::MAML3 Fusion in an Aggressive Mesenchymal Neoplasm
NR1D1‐rearranged tumors are distinct mesenchymal neoplasms with epithelioid morphology and aggressive potential. This report presents an 85‐year‐old male with a slow‐growing sternal mass identified as a pseudo‐cyst, characterized by a dense proliferation of epithelioid tumor cells. These cells exhibited pale cytoplasm and uniform oval nuclei, with some areas of spindle cells and extensive necrosis. The mitotic count was 12 per 1.7 mm2. Immunohistochemical analysis showed positivity for EMA, ERG, AE1AE3, and CK7, but negativity for SMA, desmin, CD117, CD31, SOX10, MelanA, synaptophysin, INSM1, CK20, CD34, TTF1, WT1, caldesmon, myogenin, and collagen IV. INI1 expression was preserved. The Ki67 index was high. Whole‐transcriptome sequencing revealed an in‐frame NR1D1::MAML3 fusion, retaining two key protein domains of NR1D1. Nine months post‐diagnosis, the patient developed pleural, bilateral lung, and bone metastases. This case underscores the necessity of molecular analysis for precise tumor classification, given the tumor's varied morphological features and poor prognosis.
- 13 December 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 769-771
Comment on ‘Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder’ by Wobser et al.
Identifying pathognomonic features that differentiate primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) from other CD8+ aggressive lymphomas is a major concern. Doing so can facilitate diagnosis and allow clinicians to optimize clinical management. In this context, we read with great interest the article from Wobser et al., which proposed a molecular characterization of five cutaneous acral CD8+ TLPDs and identified KIR3DL1 alterations in addition to PIK3R1 alterations. To broaden this spectrum, we propose genomic profiling of six cutaneous acral CD8+ TLPDs from our database and identify alterations related to oncogenic pathways such as the AKT pathway and the Janus kinase–signal transducer and activator of transcription protein pathway. We also confirm the decreased mRNA expression of KIR3DL1 in this setting.
- 13 December 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (4) , 769-771
Comment on ‘Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder’ by Wobser et al.
Identifying pathognomonic features that differentiate primary cutaneous acral CD8+ T-cell lymphoproliferative disorder (TLPD) from other CD8+ aggressive lymphomas is a major concern. Doing so can facilitate diagnosis and allow clinicians to optimize clinical management. In this context, we read with great interest the article from Wobser et al., which proposed a molecular characterization of five cutaneous acral CD8+ TLPDs and identified KIR3DL1 alterations in addition to PIK3R1 alterations. To broaden this spectrum, we propose genomic profiling of six cutaneous acral CD8+ TLPDs from our database and identify alterations related to oncogenic pathways such as the AKT pathway and the Janus kinase–signal transducer and activator of transcription protein pathway. We also confirm the decreased mRNA expression of KIR3DL1 in this setting.
- Open Access
- 20 November 2024
- Published by Wiley in Histopathology
- Vol. 86 (4) , 571-584
Recurrent GRHL fusions in a subset of sebaceoma: microscopic and molecular characterisation of eight cases
Aims: Sebaceous neoplasms constitute a group of adnexal tumours, including sebaceous adenoma, sebaceoma and sebaceous carcinoma. Although mismatch repair deficiency may be observed, the nature of the genetic alterations contributing to the development of most of these tumours is still unknown. In the present study, we describe the clinical, microscopic, and molecular features of eight sebaceomas with GRHL gene rearrangement.Methods and results: Among these sebaceomas, four occurred in women and four in men; the median age was 63 years (range = 29–89). The tumours were located in the head and neck area in all cases. Microscopic examination revealed a well‐demarcated lesion located in the dermis with focal extension into the subcutaneous tissue (three cases). The neoplasms displayed macronodular (eight cases), cribriform (seven cases) and organoid (six cases) growth patterns, occurring in combination. The tumours were mainly composed of immature basophilic cells associated with scattered mature sebocytes. Numerous small infundibular cysts were present in seven cases. Mitotic activity was low (none/one to four mitoses/mm2). Immunohistochemistry showed positivity for androgen receptor and p63. Preserved expression of MLH1, PMS2, MSH2 and MSH6 was observed in all cases. RNA‐sequencing revealed RCOR1::GRHL2 (three cases), BCL6::GRHL1 (two cases), a BCOR::GRHL2 (one case), RCOR1::GRHL1 (one case) and TLE1::GRHL1 (one case) fusion transcript. Methylation analysis demonstrated that GRHL‐fused sebaceomas form an independent cluster and highlight the proximity of such tumours with poromas with folliculo‐sebaceous differentiation.Conclusions: In conclusion, we report recurrent fusions of the GRHL genes in a distinctive subset of sebaceomas harbouring infundibulocystic differentiation, a frequent organoid growth pattern and lack of mismatch repair deficiency.
- 20 November 2024
- Published by Wiley in Histopathology
- Vol. 86 (4) , 571-584
Open AccessRecurrent GRHL fusions in a subset of sebaceoma: microscopic and molecular characterisation of eight cases
Aims: Sebaceous neoplasms constitute a group of adnexal tumours, including sebaceous adenoma, sebaceoma and sebaceous carcinoma. Although mismatch repair deficiency may be observed, the nature of the genetic alterations contributing to the development of most of these tumours is still unknown. In the present study, we describe the clinical, microscopic, and molecular features of eight sebaceomas with GRHL gene rearrangement.Methods and results: Among these sebaceomas, four occurred in women and four in men; the median age was 63 years (range = 29–89). The tumours were located in the head and neck area in all cases. Microscopic examination revealed a well‐demarcated lesion located in the dermis with focal extension into the subcutaneous tissue (three cases). The neoplasms displayed macronodular (eight cases), cribriform (seven cases) and organoid (six cases) growth patterns, occurring in combination. The tumours were mainly composed of immature basophilic cells associated with scattered mature sebocytes. Numerous small infundibular cysts were present in seven cases. Mitotic activity was low (none/one to four mitoses/mm2). Immunohistochemistry showed positivity for androgen receptor and p63. Preserved expression of MLH1, PMS2, MSH2 and MSH6 was observed in all cases. RNA‐sequencing revealed RCOR1::GRHL2 (three cases), BCL6::GRHL1 (two cases), a BCOR::GRHL2 (one case), RCOR1::GRHL1 (one case) and TLE1::GRHL1 (one case) fusion transcript. Methylation analysis demonstrated that GRHL‐fused sebaceomas form an independent cluster and highlight the proximity of such tumours with poromas with folliculo‐sebaceous differentiation.Conclusions: In conclusion, we report recurrent fusions of the GRHL genes in a distinctive subset of sebaceomas harbouring infundibulocystic differentiation, a frequent organoid growth pattern and lack of mismatch repair deficiency.